Vermillion, Inc. (VRML)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.11+0.07 (+6.73%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.04
Bid0.95 x 1000
Ask5.03 x 200
Day's Range1.01 - 1.11
52wk Range0.92 - 2.20
1y Target EstN/A
Market Cap57.97M
P/E Ratio (ttm)-3.02
Avg Vol (3m)41,876
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Vermillion CEO to Present at Women in Bio - New York

    AUSTIN, Texas, Oct. 19, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that CEO, Valerie Palmieri, will present ...

  • PR Newswire25 days ago

    ASPiRA LABs OVA1® Test Now Covered By CareFirst BlueCross BlueShield

    AUSTIN, Texas, Sept. 29, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contract agreement with CareFirst BlueCross BlueShield for their U.S. FDA cleared ...

  • PR Newswirelast month

    Vermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening

    AUSTIN, Texas, Sept. 9, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (VRML), today announced its support for the recent US Food and Drug Administration (FDA) safety communication which recommends against the use of any screening tests for ovarian cancer. Earlier this week, the FDA announced that it is alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests.